Skip to content
Open access

Expression of Active Apurinic Apyrimidinic Endodeoxyribonuclease 1 in Human Platelets

Aug 2026 · The FASEB Journal · Vol 40 · 0 citations · 17 references
Medicine

TL;DR

The first evidence for the expression levels and subcellular localization of apurinic/apyrimidinic endodeoxyribonuclease 1 (APE1), evaluated alongside cytosolic and mitochondrial markers, in resting human PLTs isolated from a cohort of healthy donors is provided.

Abstract

The pivotal role of platelets (PLTs) in hemostasis, thrombosis, innate immunity, and tissue repair is sustained by mitochondria, whose dysfunctions can impair ATP generation and redox signaling, thus affecting optimal levels of PLTs' functionality. Maintenance of mtDNA integrity is essential for mitochondria functioning and is primarily exerted by the base excision repair (BER) pathway, never described in PLTs. Here, we provide the first evidence for the expression levels and subcellular localization of apurinic/apyrimidinic endodeoxyribonuclease 1 (APE1), evaluated alongside cytosolic and mitochondrial markers, in resting human PLTs (huPLTs) isolated from a cohort of healthy donors. A variable expression of APE1 was detected independently of age and sex, and it was found to correlate with the specific enzymatic activity on canonical and far less on noncanonical substrates. Preliminary experiments with an APE1 enzymatic inhibitor suggest a possible involvement of APE1 in PLTs aggregation stimulated by epinephrine. Overall, our findings pave the way for understanding a novel unforeseen role of APE1 in PLTs physiology, which specifically deserves future investigation.

Read PDF

Similar papers

Open access Aug 2026

Molecular Striptease of a Thiadiazolopyrimidine Hit Yields a Streamlined, Artifact-Free NADPH Mimic for NOX Inhibition

Compound 5, although aqueous solubility issues limited its cellular antiproliferative performance, represents a specific, artifact-free architectural starting point for future selective NOX inhibitor development.

Emanuele Fabbrizi, Andrea Mancini, Chiara Lambona et al. · 0 citations
Open access Jul 2026

Complement drives PNH red cell hemolysis independently of inflammasome activation

It is shown that the destruction of PNH erythrocytes is a consequence of the MAC-calcium-calpain axis, rather than an inflammatory programmed cell death event, which means therapeutic strategies aimed at targeting the inflammasome or caspase signaling will likely offer no clinical benefit for PNH patients.

N. Ranjan, M. Cole, G. Gerber et al. · 0 citations
Open access Jul 2026

A Procoagulant Peptide Analog of the SARS-CoV-2 Nucleocapsid C-terminal Domain

The results support a model in which N389 functions as a stable, charge-based scaffold that coordinates divalent cations and/or directly nucleates fibrin(ogen), while highlighting limitations of bulk clotting assays and the need for targeted thrombin generation, binding, aggregation, and contact-activation studies.

B. Pollo, F. M. Climacosa, S. Caoili · 0 citations
Open access Aug 2026

Antimicrobial cetylpyridinium chloride disrupts the mitochondrial electron transport chain as potently as cyanide, via cardiolipin interference at cytochrome C

CPC exhibits mitotoxicity as potent as cyanide, and the precise biochemical mechanism of action of this ubiquitous compound is determined to aid epidemiology, risk analysis, and predictive toxicology.

Emily L. Ledue, Noah E. Adelman, Madeleine K. Lorenger et al. · 0 citations
Open access Jul 2026

Adenylosuccinate acts as a novel pro-angiogenic factor

We recently demonstrated a dramatic 77-fold increase in brain adenylosuccinate (AdSucc) concentration during ischemia, reaching ~0.56 mM levels. Previously, the role of AdSucc induction under decreased energy charge was attributed to the activation of purine nucleotide (PNC) and the tricarboxylic acid cycle (TCA). Howe...

Brennon Schofield, D. Seeger, Derek Besch et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.